WHO ICTRP trial
Evaluation of immunogenicity and safety of two 2-dose Human Papillomavirus (HPV)…
EUCTR2011-000757-22-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-000757-22-DE |
|---|---|
| Public title | Evaluation of immunogenicity and safety of two 2-dose Human Papillomavirus (HPV) vaccine schedules in 9-14 year old girls. |
| Scientific title | A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to alternative 2-dose schedules in 9 - 14 year old healthy females compared to the… |
| Primary sponsor | GlaxoSmithKline Biologicals |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Taiwan;Canada;Thailand;Germany;Italy |
| Conditions | Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic human… |
| Interventions | Trade Name: Cervarix Pharmaceutical Form: Suspension for injection in pre-filled syringe Other descriptive name: HUMAN PAPILLOMAVIRUS VACCINE [TYPES 16, 18] (RECOMBINANT, ADJUVANTED, ADSORBED) Concentration unit: µg/ml… |
| Registration date | Apr 28, 2011 |
| Target size | 1428 |
| Secondary IDs | 114700 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: